2019
Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease
Coleman E, Panse G, Cowper S, Prebet T, Gore S, Leventhal J. Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. Journal Of Cutaneous Pathology 2019, 46: 930-934. PMID: 31254406, DOI: 10.1111/cup.13537.Peer-Reviewed Original ResearchConceptsLobular neutrophilic panniculitisNeutrophilic panniculitisDNA methyltransferase inhibitorNeutrophilic eccrine hidradenitisInjection site reactionsAcute myelogenous leukemiaMethyltransferase inhibitorNeutrophilic dermatosisSweet's syndromeMaculopapular eruptionCutaneous toxicityHistopathologic characteristicsSite reactionsNext-generation agentsDifferential diagnosisMyelogenous leukemiaTreatment considerationsMyeloid diseasesPanniculitisTreatmentInhibitorsFirst reportGangrenosumHidradenitisEcchymosis
2017
Well‐differentiated neuroendocrine tumors in skin: Terminology and diagnostic utility of cytokeratin 5/6 and p63
Panse G, Cowper SE, Leffell DJ, Pulitzer M, Ko CJ. Well‐differentiated neuroendocrine tumors in skin: Terminology and diagnostic utility of cytokeratin 5/6 and p63. Journal Of Cutaneous Pathology 2017, 44: 557-562. PMID: 28417484, DOI: 10.1111/cup.12952.Peer-Reviewed Original ResearchConceptsCutaneous adnexal neoplasmsAdnexal neoplasmsNeuroendocrine tumorsAdnexal tumorsBenign skin adnexal tumorCutaneous adnexal tumorsAggressive metastatic diseaseLow-grade tumorsSkin adnexal tumorsMajority of casesMetastatic diseaseMetastatic adenocarcinomaCarcinoid tumorsCytokeratin 5/6Diagnostic challengeDifferential diagnosisImmunohistochemical stainsCK5/6Diagnostic utilityPrimary siteTumorsNeoplasmsFirst signWDNETsP63